Progressing with the development of small-molecule inhibitors targeting ferrochelatase (FECH) opens a significant pathway for broadening treatment options for neovascular eye disease patients resistant to current anti-VEGF therapies, addressing a vital medical need. Here, FECH is linked to eye disorder.